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ABSTRACT 
 
Introduction 
Liver transplantation is currently the only effective therapy for patients with end 
stage acute or chronic liver failure. The increasing request of organs has led to the 
more extensive use of the so-called marginal donors, in particular donors after 
circulatory death (DCD). 
Within this model of donation, a more severe degree of ischaemia-reperfusion 
injury (IRI) is occurring, that seems to play a role on the pathogenesis of local and 
remote organ complications. 
This research will focus on the influence of liver graft injury on the pathogenesis of 
local and remote organ complications, evidencing the role of IRI leading to biliary 
complications and development of systemic inflammatory response associated with 
the occurrence of acute kidney injury (AKI).  
Aim of the study was to assess the role of IRI in two different models of ischaemia, 
DCD and donation after brain death (DBD), in liver transplanted grafts, on the 
pathogenesis of local and remote organ complications.  
We evaluated the development of biliary complications and its association with the 
degree of donor liver graft bile duct injury after liver reperfusion. 
Moreover, the development of AKI after liver transplantation was considered, as 
consequence of IRI and systemic inflammatory response.  
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Methods 
Retrospective single-centre study of adult patients who underwent liver transplantation 
at University Hospital Birmingham (UHB) National Health Service (NHS) Foundation 
Trust from January 2007 to December 2014. 
Characteristics of recipient at transplant, recipient renal and liver function in the 
immediate pre-transplant period, donor and graft variables, intra-operative parameters, 
indicators of initial graft function and renal function in the post-transplant period were 
considered. 
Primary end points were the occurrence of biliary complications, in particular 
ischaemic cholangiopathy (IC), and development of AKI. Secondary end point was 
the evaluation of IRI damage on the basis of transaminases, bilirubin and INR over the 
first week post-transplant and the appearance of bile duct retrieved after liver 
reperfusion on histological examination. 
Severity of donor bile duct injury was assessed and scored on the basis of biliary 
epithelial cell loss, mural stroma necrosis, inflammation, peribiliary vascular plexus 
(PVP) damage, arteriolonecrosis, thrombosis, periluminal and deep peribiliary glands 
(PBGs) damage.  
Cholangiocyte apoptosis in periluminal and deep PBGs was evaluated by 
quantitative terminal deoxy-nucleotidyl transferase dUTP-mediated nick-end labeling 
(TUNEL) analysis on bile duct sections. Cholangiocyte proliferation was studied in 
bile duct sections by PCNA immunohistochemical expression. 
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Results 
One thousand and 60 liver transplant recipients (813 from DBD and 247 from DCD) 
were considered. 
Recipients from DCD had higher ALT and AST in the first 7 days after transplant, 
compared to DBD. The occurrence of biliary complications was higher in DCD liver 
transplant recipients (85/247; 34%) compared to DBD (166/813; 20%) (p<0.001), in 
particular IC incidence was significantly higher in DCD. 
The incidence of AKI was 59.3% (629/1060 recipients) and was significantly 
higher in DCD (160/247, 64.8%) compared to DBD (469/813, 57.7%) recipients 
(p=0.047). 
Sixty-two patients comparable with the entire cohort, had the bile duct sample 
available for histological evaluation. A significantly higher number of DCD patients 
presented necrosis >50% of the bile duct wall [DCD 14/28 (50%), DBD 9/34 (26.5%) 
p=0.056], PVP damage [DCD 8/28 (29%), DBD 3/34 (9%); p=0.053] and periluminal 
PBGs damage [DCD 20/28 (71%), DBD 14/34 (41%); p=0.016]. These features 
defined the occurrence of severe histological injury, that was significantly more 
frequent in DCD liver transplant patients [15/28 (53.6%)] compared to DBD [7/34 
(20.6%)] (p=0.007). A significant increased apoptosis and decreased proliferation was 
evidenced in both periluminal (Tunel assay p=0.029; PCNA expression p=0.029) and 
deep PBGs (Tunel assay p=0.002; PCNA expression p=0.006) from bile duct sample 
with severe histological injury. 
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Discussion 
A more severe degree of IRI is occurring within DCD, as evidenced by greater graft 
dysfunction and increasing peak perioperative transaminases, likely related to the 
added donor warm ischaemia time.  
The IRI seems to play a role on the pathogenesis of local and remote organ 
complications, evidencing the role exerted in DCD leading to biliary complications 
and development of systemic inflammatory response associated with the occurrence 
of AKI. 
This study also shows an early picture of microscopic damage at the level of the 
bile duct soon after reperfusion of liver graft during transplantation. Bile duct samples 
retrieved from DCD grafts expressed more severe injury at the histological level, as 
evidenced by the increased incidence of mural stroma necrosis, PBP damage and PBG 
damage, defining the new feature of severe histological injury.  
Bile ducts with severe histological injury showed increased apoptosis and reduced 
proliferation, as evaluated by Tunel assay and PCNA expression, both on periluminal 
and deep PBG cholangiocytes. 
The higher incidence of IC development in DCD strongly suggests a relation 
between the occurrence of severe histological injury and alteration in bile duct repair 
mechanisms, raising hypothesis to further evaluate those mechanisms leading to the 
development of bile duct non-anastomotic strictures. 
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INTRODUCTION 
 
Over the past 40 years, orthotopic liver transplantation has evolved from an 
experimental procedure to become the treatment of choice for patients with end-stage 
liver failure (ESLD). The first few liver transplants by T.E. Starzl in 1963 were not 
successful but showed the feasibility of the surgical technique and four years later he 
reported patient survival beyond one year. These early attempts at liver transplantation 
were in high-risk patients and the problems of controlling hemorrhage and coagulopathy 
and poor graft function resulted in significant intra-operative and early postoperative 
mortality. In these early series, the one-year survival after liver transplantation in both 
adults and children was only 19%. 
Prednisolone and azathioprine were the primary immunosuppressive drugs, but some 
regimens included combinations of cyclophosphamide, antilymphocyte globulin, 
splenectomy, total body irradiation and thymectomy. One-year survival after liver 
transplantation, however, remained poor and was only 30% in 1978. 
The introduction of cyclosporin in 1981 transformed clinical practice because of 
the improved outcome following liver transplantation. The National Institute of Health 
Consensus Conference in 1983 concluded that liver transplantation for end-stage liver 
disease deserved broad application and should be considered a therapeutic option rather 
than an experimental procedure. 
Liver transplantation is currently the only effective therapy for patients with end 
stage acute or chronic liver failure. Advances in immunosuppressive therapy, organ 
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preservation, surgical and anaesthetic techniques and improved management of post-
transplantation complications have led to further improvement in survival. Currently 
patients with chronic liver disease undergoing liver transplantation can anticipate a 
one-year survival of 85% and a 5-year survival of greater than 75%. 
Nevertheless, the procedure of liver transplantation is still associated with a series 
of significant complications. Transplantation of the liver leads to hepatic-ischaemia 
reperfusion injury (IRI), the damage occurring for the duration of several phases: 
during warm ischemia time, during cold preservation throughout and following the 
retrieval of the liver and within warm reperfusion at implantation to the recipient. 
Hepatic ischemic-reperfusion injury is a complex process that results in apoptosis or 
necrosis of hepatic cells and activation of the inflammatory response. An inflammatory 
response associated with the expression of pro-inflammatory cytokines has been 
reported in consequence of liver reperfusion in both animals and humans (Colletti et 
al, 1996; Bellamy et al, 1997; Monbaliu et al, 2007). Numerous cell types and 
molecular mediators act in a complex communication networks involving the immune 
and non-immune systems to initiate and propagate IRI (Abu-Amara et al, 2010). 
Two different models of donation are nowadays available, donation after 
circulatory death (DCD) and donation after brain death (DBD), that are characterized 
by different degree of IRI in relation to retrieval modalities. 
This research will focus on the influence of liver graft injury on the pathogenesis of 
local and remote organ complications, evidencing the role of IRI leading to biliary 
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complications and development of systemic inflammatory response associated with 
the occurrence of acute kidney injury (AKI).  
 14 
AIM OF THE STUDY 
 
Aim of the study was to assess the role of ischaemia-reperfusion injury in two 
different models of ischaemia, DCD and DBD, in liver transplanted grafts, on the 
pathogenesis of local and remote organ complications.  
We evaluated the development of biliary complications and its association with the 
degree of donor liver graft bile duct injury after liver reperfusion. 
Moreover, the development of acute kidney injury after liver transplantation was 
considered, as consequence of IRI and systemic inflammatory response.  
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SCIENTIFIC BACKGROUND 
 
Extended criteria donors – donation after circulatory death 
 
Liver transplantation has become victim of its own success, with the increasing 
number of patients awaiting a transplant not faced with the same increasing of organs 
donation. The shortage of donor organs prompted the development of newer 
techniques like transplantation of reduced-size organs for small children, of split livers 
(one donor organ split into two segmental liver grafts) and living-related liver 
transplantation. However, this has not satisfied the increasing discrepancy between 
resources and needs, leading to the use of the so-called marginal donors, which for 
reasons of age or non-ideal systemic and/or graft conditions, question the real fitness 
of the donor. 
Within this group a substantial portion comprises donors after circulatory death 
(DCD). Donors after circulatory death are patients with brain injury incompatible with 
recovery whose condition does not meet formal criteria for brain stem death and whose 
cardiopulmonary function ceases before organs are retrieved. In the 1960’s DCD were 
the main source of allografts until the Harvard definition and criteria for brain death 
were published in 1968. Following the introduction of brain stem death criteria, 
interest in DCD declined because of the better results obtained with organs from heart 
beating donors. Renewed interest in DCD occurred because of the current organ 
shortage, improvements in organ preservation, immunosuppression and surgical 
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techniques, and changing neurosurgical practice in the management of traumatic head 
injuries. 
Donation after circulatory death can be categorised into 2 groups: controlled and 
uncontrolled. Controlled donation takes place when the death occurs within an 
intensive care/hospital setting and there is a planned withdrawal of therapy by the 
patient’s medical team. Uncontrolled donation occurs outside the hospital or within 
the emergency room and is unpredictable.  
The several reports regarding liver transplantation from DCD have shown a 
progressive reduction in the incidence of primary non-function in recent years due to 
a shift towards controlled donation, better donor selection and shorter warm and cold 
ischaemic times. 
The long-term outcome for liver transplantation from DCD donors has been 
considered inferior to organs from DBD donors (Selck FW, et al. 2008; Yamamoto S, 
et al. 2010). Recent reports suggest comparable outcomes for DBD and DCD livers 
after transplantation (Dubbeld J, et al. 2010; Fujita S, et al. 2007). It is also becoming 
apparent that the outcome of DCD livers depends on a number of donor and recipient 
factors and technical factors in relation to the organ retrieval and implantation (Mathur 
AK, et al. 2010). An important role has been recognised for duration of both primary 
warm and cold ischaemia time (pWIT and CIT, respectively), which are associated 
with recipient complications, specifically for ischaemic cholangiopathy, graft failure 
and recipient mortality (Taner CB, et al. 2012; Hong JC, et al. 2011). 
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Currently, DCD account for about 26% of livers transplanted in United Kingdom 
(Annual Report on Liver Transplantation 2015/16 – NHS Blood and Transplant). 
Patients are considered for liver donation provided they have good liver and renal 
function and after explicit consent is obtained from relatives. A minimum waiting 
period of 5 minutes after cardiac arrest is observed before starting the retrieval 
procedure following the recommendations of the Institute of Medicine. The transplant 
team must not be involved in decisions regarding the modality and logistics of 
withdrawal and these are undertaken by the intensive care physician and according to 
local hospital policies. Similarly, the transplant team plays no part in the declaration 
of death. 
Suitability of the DCD livers for transplantation is initially assessed at retrieval. 
Factors considered in making the decision include the time between withdrawal of 
therapy and death and the period of warm ischaemia. Retrieval of the liver is not 
considered if cardiac arrest does not occur within one hour of withdrawal because of 
damage resulting from prolonged periods of hypotension. During the donor procedure, 
the liver is assessed macroscopically for the presence of fatty change, perfusion quality 
and physical characteristics. 
The organ donation procedure occurs in accordance to the UK National standards 
and local guidelines. After death certification and the obligatory no-touch period of 5 
minutes a rapid access of the vessels is gained and cannulation performed. Usual 
retrieval process follows, with cold preservation of the liver graft until the implantation 
into the recipient. (Figure 1) 
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Hepatic ischemia reperfusion injury and systemic inflammatory response 
 
The ischemic phase, lacking oxygen supply, leads to depletion of adenosine 
triphosphate (ATP) in Kupffer cells (KCs), hepatocytes and sinusoidal endothelial 
cells (SECs), with a consequent loss of intracellular ion homeostasis, oedema, swelling 
and cell death (Selzner M, et al. 2007).  
A series of danger-associated molecular patterns (DAMPs) are released by necrotic 
cells or secreted by stressed or injured cells, with the ability to initiate and propagate 
the inflammatory response binding to pattern recognition receptors expressed on cells 
of the innate immune system. During IRI, DAMPs are released, which are reported to 
interact with toll-like receptors (TLRs) and receptors for the advanced glycation end 
products (RAGE), resulting in cytokines release and neutrophils (polymorphonuclear 
monocytes - PMNs) and leukocyte recruitment and activation with extension of liver 
injury (Abu-Amara M, et al. 2010). 
Concurrent activation of the complements system occurs, leading to liver damage 
directly mediated by lysing of hepatic cells by the membrane attack complex or by 
activating KCs and recruiting and triggering PMNs (Arumugam TV, et al. 2004; 
Fondevila C, et al. 2008). Complement activation is also involved in remote organ 
damage secondary to IRI (Inderbitzin D, et al. 2004). 
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The activation of KCs, the liver-resident macrophages, occurs during both the 
ischemic and the reperfusion phases, leading to release of reactive oxygen species 
(ROS), tumor necrosis factor (TNF)- and interleukin (IL)-1 (Llacuna L, et al. 2009). 
These mediators work to recruit and activate PMNs s and CD4+ lymphocytes, to 
stimulate SECs to express cell-surface adhesion molecules for PMNs and platelets 
adhesion and to trigger hepatocytes to release ROS. The same mediators are 
responsible for the direct damage of SECs and hepatocytes (Hanschen M, et al. 2008; 
Taniai H, et al. 2004; Nakano Y, et al.2008). Sinusoidal endothelial cells dysfunction 
is further enhanced by the depletion of nitric oxide resulting in a vasoconstrictive state. 
Neutrophils accumulate in the swollen and constricted hepatic sinusoids early in 
response to inflammatory mediators, and the adhesion to target cells leads to fully 
degranulation with release of proteases and myeloperoxidase and production of ROS. 
These can diffuse into cells generating an intracellular oxidant stress resulting in 
disruption of cellular calcium homeostasis, damage to mitochondria and necrotic cell 
death, while proteases produce cell killing and proinflammatory mediators (Jaeschke 
H, 2006). 
CD4+ T lymphocytes accumulate early in the liver after IRI. These have an 
important role in recruiting PMNs and secreting interferon- (IFN-), which stimulates 
KCs to release TNF- and IL-1 and hepatocytes to release chemokines (Caldwell CC, 
et al. 2007). 
Tumor necrosis factor- holds the central role in the pro-inflammatory cytokine 
pathways activated by the IRI. It is identified as crucial inducer of apoptotic cell death 
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of hepatocytes, associated with the increase of aspartate aminotransferase (AST) as 
sensitive marker of hepatocyte injury (Rudiger HA and Clavien PA, 2002). TNF- 
activates specific receptors on hepatocytes, TNF-receptor 1 (TNF-R1), connected to a 
cytoplasmatic region called "death domain," which activates specific caspases with 
subsequent selective release of mitochondrial proteins such as cytochrome C, leading 
to morphological changes of cellular structure as well as degradation of DNA and 
finally to cell death (Yuan J, 1997). TNF- also mediates the recruitment of PMNs to 
the liver as well as the release of reactive oxygen species (ROS) from hepatocytes 
(Schwabe RF and Brenner DA, 2006). It is principally released by activated KCs and 
acts both locally in a paracrine manner and remotely as a decisive player of remote 
organ damage (Colletti L, et al. 1990). 
Allograft damage resulting from the transplantation process, commonly defined as 
preservation injury, is a major contributor to primary allograft dysfunction and is 
reported to be related with the presence of sinusoidal neutrophilia and hepatocellular 
necrosis in post-reperfusion biopsy (Gaffey MJ; et al. 1997). Primary non-function 
(PNF) of the liver graft is the most feared complication of severe preservation injury 
representing a life-threatening problem, but early allograft dysfunction is also 
associated with >10-fold increase in the risk of death (Olthoff KM, et al. 2010). The 
extent of hepatocellular damage is assessed according to AST levels and peak AST 
well correlates with the histological grade of hepatic preservation injury (Hilmi I, et 
al. 36,37).  
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The systemic release of pro-inflammatory cytokines such as TNF-, IL-1, IL-6 
and IL-8, subsequent to reperfusion is possibly involved together with the cellular 
damage in hemodynamic changes, described as post-reperfusion syndrome, occurring 
after liver reperfusion.  
Post-reperfusion syndrome is defined in its severity by the effects on cardiovascular 
parameters (Paugam-Burtz C, et al. 2009) and it is associated with a lower early 
survival and an increased post-operative renal failure (Ramsay M, 2008). 
These changes in cytokines concentrations and hemodynamic, responsible for the 
systemic inflammatory response triggered by IRI, resemble those seen in sepsis 
syndrome (Bellamy MC, et al. 1997).  
Donation after circulatory death is characterized by more severe degree of IRI as 
evidenced by greater graft dysfunction and increasing peak perioperative aspartate 
aminotransferase. The key mediator of this greater graft dysfunction is hypothesized 
to be the added donor warm ischemic time. Warm ischemia duration correlates with 
the postoperative systemic inflammatory response (Leithead JA, et al. 2012). 
 
 
Local complications: the bile duct 
 
The biliary tree is a complex network of conduits that begins with the canals of 
Hering and progressively merges into a system of interlobular, septal, and major ducts 
which then coalesce to form the extrahepatic bile ducts, which finally deliver bile to 
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the gallbladder and to the intestine. Bile ducts run in parallel with a branch of the portal 
vein and with one or two branches of the hepatic artery, giving rise to a close anatomic 
association classically represented in the liver microarchitecture by the portal triad. 
(Carruthers JS and Steiner JW, 1961).  
According to the ductal diameter, the human intrahepatic bile duct can be classified 
into: small bile ductules (diameter <15 μm), interlobular ducts (15–100 μm), septal 
ducts (100–300 μm), area ducts (300–400 μm), segmental ducts (400–800 μm), and 
hepatic ducts (>800 μm) (Carruthers JS and Steiner JW, 1961).  
Cholangiocytes line the bile ducts, showing a morphological heterogeneity that is 
strictly associated with a variety of functions performed at the different levels of the 
biliary tree. (Alpini G, et al. 1997). 
In addition to rerouting bile into the intestine, cholangiocytes are actively involved 
in absorption and secretion to produce the final bile composition. More recently, 
cholangiocytes lining the smaller bile ducts have been demonstrated to directly react 
to several insults with specific properties such as the ability to undergo limited 
phenotypic changes, the ability to participate in the inflammatory reaction to liver 
damage and the ability to behave as liver progenitor cells (Sell S, 2001). 
The small ductules are lined by four to five cholangiocytes, morphologically 
characterized by a cuboidal shape, with a basement membrane, tight junctions between 
adjacent cells and microvilli projecting into the bile duct lumen Cholangiocytes 
become larger in size and more columnar in shape with the progressive enlargement 
of the ductal system. (Benedetti A, et al. 1996). 
 23 
In addition to morphological heterogeneity, cholangiocytes display ultrastructural, 
antigenic, functional and proliferative heterogeneous responses (Alpini G, et al. 1996; 
Benedetti A, et al. 1996 Kanno N, et al. 2000; Glaser SS, et al. 2009). 
Recent studies of cholangiocytes at the ultrastructural level have shown phenotypic 
differences between those lining small and large bile ducts. Small cholangiocytes 
possess cuboidal shape and show a high nucleus to cytoplasm ratio (Benedetti A, et al. 
1996). This aspect is typical of poorly differentiated cells in which it occurs an intense 
synthesis of RNA messenger but lower post-transcriptional activity. Conversely, large 
cholangiocytes have columnar shape and are characterized by a relatively small 
nucleus and abundant cytoplasm (Alpini G, et al. 1996; Kanno N, et al. 2000; LeSage 
G, et al. 2000). A rich Golgi apparatus is detectable between the apical pole and the 
nucleus, whereas rough endoplasmic reticulum is scarce in the smallest ductules, and 
increased only slightly in the large ducts (Benedetti A, et al. 1996).  
Both small and large cholangiocytes express cytokeratin-7 and -19, alkaline 
phosphatase, whereas only large cholangiocytes the secretin receptor, cystic fibrosis 
transmembrane conductance regulator (CFTR) and chloride bicarbonate anion 
exchanger 2 (Cl-/HCO-3 AE2) and respond to secretin with enhanced secretory and 
proliferative activities (Alpini G, et al. 1998; Alpini G, et al. 1997). 
This morphological heterogeneity is associated with a variety of different functions 
performed by cholangiocytes at different levels of the biliary tree: beyond funneling 
the bile into the intestine, cholangiocytes also are actively involved in bile production 
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by performing both absorbitive and secretory functions as well as in 
regenerative/reparative processes.  
Cholangiocytes in the adult liver are quiescent (LeSage GD, et al. 1999), since they 
express factors such as cyclin dependent kinase inhibitors p27, bcl2 and BclxL that are 
responsible for this mitotically dormant state (Harnois DM, et al. 1997). However, in 
pathological states cholangiocytes become mitotically activated both in experimental 
cholestasis (e.g., BDL and A feeding) (Alpini G, et al. 1988) and in human 
cholangiopathies such as PBC and PSC classified as “vanishing bile duct syndrome” 
(Desmet VJ, et al. 1998).  
In contrast to hepatocytes, the biliary epithelium is specifically nourished by 
terminal branches of the hepatic artery, which constitute a complex vascular system 
called the peribiliary vascular plexus (PVP), which is crucial for maintaining integrity 
and function of the biliary epithelium (Kono N and Nakanuma Y, 1992). They 
originate from the terminal branches of the hepatic artery and deliver blood to the 
sinusoids into the portal vein (Gaudio E, et al. 1996). This specific vascular supply, 
lacking in canals of Hering and terminal cholangioles, accounts for the prevalent 
involvement of the interlobular bile ducts in case of ischemic injury due to obstruction 
of hepatic artery branches less than 200 mm in diameter, featuring the ‘‘ischemic 
cholangiopathy’’ (Deltenre P and Valla DC, 2006).  
The function of the intrahepatic biliary epithelium is linked to its vascular supply 
sustained by the PVP (Gaudio E, et al. 2006), since alterations of intrahepatic bile 
duct mass are associated with architectural changes in the PVP (Gaudio E, et al. 
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2006/2). The PVP stems from the hepatic artery, nourishes the biliary tree, and 
sustains a countercurrent of substances reabsorbed from bile toward parenchymal 
cells (Gaudio E, et al. 1996). After BDL, the increase in intrahepatic bile duct mass 
is followed by a parallel growth of the PVP, which is fundamental in sustaining the 
enhanced nutritional and functional demands of the proliferating biliary epithelium 
(Gaudio E, et al. 2005). Nevertheless, the proliferation of the PVP occurs only after 
the hyperplasia of the biliary epithelium (Gaudio E, et al. 1996), suggesting a cross-
talk mechanism between cholangiocytes and endothelial cells, an interaction that 
mediates the adaptive changes of these cells during liver damage (Gaudio E, et al. 
2006).  
 
 
Biliary complications in liver transplantation 
 
Biliary complications continue to be one the main causes of morbidity and mortality 
after liver transplantation, with stenosis and fistulae being the most common problems 
(Buck DG and Zajko AB. 2008). 
Bile duct strictures post liver transplant can be classified on the basis of localization 
as anastomotic strictures and non-anastomotic strictures (NAS). These have different 
aetiology and time of development after transplant (Buis CI, et al. 2007).  
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Anastomotic strictures are mainly related to the surgical technique of the 
anastomosis (choledocho-choledochostomy or choledohco-jejunostomy), while NAS 
recognize a multifactorial aetiology not entirely defined yet. 
Non-anastomotic strictures were originally reported after hepatic artery thrombosis 
(HAT), leading to biliary duct ischemia and necrosis. The typical characteristics of 
NAS include stenosis, dilatations and intra-duct biliary stones (Buis CI, et al. 2007). 
The same features (biliary strictures and dilatations) have been reported in the 
absence of HAT and defined ischemic cholangiopathy (IC). 
The incidence of IC after liver transplant is variable, depending on different studies 
considering different timings of follow-up and definitions, and is widely reported to 
account for 1 to15% of transplant complications (Buis CI, et al. 2006; Sharma S, et al. 
2008). 
Ischemic cholangiopathy may involve both intra- and extra-hepatic biliary tree, 
usually develop over the first few weeks to 1 year after transplantation and strongly 
influence graft and patient survival.  
The underlying pathogenic mechanism of IC is not yet completely understood. 
Reported risk factors for IC include donor older age, DCD, longer cold and warm 
ischaemia times, steatosis of transplanted organ, high viscosity preservation solution 
and prolonged use of dopamine in the donor (Jay CL, et al. 2011; DeOliveira MD, et 
al. 2011).  
Three types of injury have been hypothesized to cause IC including ischemia-
reperfusion injury to the transplanted organ, the immune-mediated damage in patients 
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with immunological primary diseases (i.e. primary sclerosing cholangitis and 
autoimmune hepatitis) and a cytotoxic injury due to hydrophobic biliary salts. 
Ischaemia-reperfusion plays an important role and the cholangiocytes lining the 
biliary ducts are very sensitive to ischaemic injury. To date, there is no universally 
accepted classification on the histological degree of bile duct damage post-liver 
transplant. Different reports have been published about the timing between 
transplantation and the occurrence of significant biliary damage. Noack et al. reported 
an increased vulnerability of cholangiocytes during the reperfusion phase (Noack K, 
et al. 1993), while Brunner et al. showed the prominent damage of bile ducts in DBD 
donors occurring after cold storage (Brunner SM, et al. 2013). Boenerth et al, 
conversely, did not demonstrate bile duct necrosis after organ retrieval and cold 
storage in an animal DCD transplant model. 
A higher incidence of IC has been reported in transplants from DCD donors 
compared to donation after DBD, probably due to the longer and complex ischemic 
damage in this model of donation. Recently op den Dries et al failed to highlight 
differences in the degree of biliary injury in terms of biliary epithelial injury, mural 
stromal necrosis, intramural bleeding, peribiliary glands (PBGs) injury and 
inflammation, in DBD and DCD livers developing IC. They only showed a 
significantly higher percentage of injury of the PVP in the DCD group (Op den Dries 
S, et al. 2014). 
Inadequate perfusion of PVP during the retrieval process has been suggested as one 
of the causes of IC development, because the small arterial plexus surrounding the 
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biliary tree could be poorly washed by some high viscosity solutions leading to micro-
thrombotic complications during the reperfusion phase that exacerbate the ischemic 
damage to the biliary cells (Polack WG and Porte RJ, 2006).  
Recently it has been demonstrated that ischaemia-reperfusion injury induces a 
functional damage of bile ducts as established by increased apoptosis of large bile duct 
in liver sections and increased expression of angiogenic factors as compensatory 
mechanisms in response to biliary damage (Mancinelli R. et al, 2015). 
 
 
Remote organ complications: the kidney in liver transplant setting 
 
Liver transplant recipients demonstrate a spectrum of renal dysfunction that affect 
the patient outcome. Portal hypertension, and the resulting circulatory and neuro-
humoral derangement, is associated with a progressive functional renal impairment. 
This first becomes evident in early compensated cirrhosis, and evolves in parallel with 
advancing disease. Pre-ascitic cirrhotic patients have impaired renal sodium 
metabolism, with reduced natruiresis in the standing position and following a saline 
load. Later, sodium excretion is reduced further, there is a positive sodium balance, 
and ascites develops. With more advanced circulatory changes, there is a progressive 
fall in total renal blood flow, which is eventually accompanied by a fall in glomerular 
filtration rate when intra-renal compensatory mechanisms fail. (Arroyo V, et al. 1996) 
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Many aetiologies of liver disease may also involve kidneys in patients undergoing 
liver transplantation, such as hepatitis C, hepatitis B, and adult polycystic liver and 
kidney disease. Twenty-five percent of listed patients have diabetes mellitus and 15% 
have hypertension (Leithead JA, et al. 2009). Furthermore, episodes of temporary 
acute kidney injury are frequent in this group (Cabezuelo JB, et al. 2006). 
The importance of renal dysfunction in liver transplant patients is well highlighted 
in the Model for End-stage Liver Disease (MELD) score, a validated measure of the 
risk of mortality in patients with end-stage liver disease, based on bilirubin levels, 
international normalized ratio (INR) and serum creatinine (Kamath PS, et al. 2001). 
MELD is used to prioritize the sickest liver transplant candidates in many countries 
worldwide since 2002 and a higher MELD score has been reported to be associated 
with the development of AKI (O’Riordan A, et al. 2007). 
 
 
Acute kidney injury post liver-transplantation 
 
AKI is a frequent complication of liver transplantation. Reported incidence rates 
vary widely, largely reflecting differing definitions of renal dysfunction.  
Recent publications using standardised criteria suggest that approximately one third 
of all liver transplant recipients develop AKI, and one quarter require renal 
replacement therapy (O’Riordan A, et al. 2007; Leithead JA, et al. 2012).  
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The well recognised clinical consequences of AKI during the immediate post-
operative period are electrolyte and acid base disturbance, and fluid overload. 
AKI after liver transplantation is multi-factorial in origin. Pre-existing renal 
dysfunction probably plays an important role; chronic kidney disease is a consistent 
risk factor for the development of AKI in other settings, possibly as a result of 
haemodynamic dysfunction and altered renal autoregulation, and an increased pre-
disposition to renal injury (Chawla LS and Kimmel PL. 2012).  
Intra-operative events play a key role in driving renal injury at the time of 
transplantation. The classical liver transplant surgery involved resection of the 
recipient retro-hepatic vena cava with secondary marked haemodynamic instability; a 
dramatic fall in cardiac pre-load and renal perfusion, and splanchnic and renal 
congestion (Fonouni H, et al. 2008). The more recently employed piggyback technique 
preserves venous continuity and has been associated with a reduced incidence of acute 
renal dysfunction (Sakai T, et al. 2010).  However, it does not avoid splanchnic 
hyperaemia as a result of portal vein clamping. In one small randomised controlled 
trial, the additional use of a temporary portocaval shunt was related to a lesser fall in 
cardiac output and greater urine output during the anhepatic phase. Yet, there was no 
convincing beneficial effect on post-operative renal function. The literature does not 
currently support veno-venous bypass on top of piggyback cava-preserving alone in 
the minimisation of renal injury (Sakai T, et al. 2010).  
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Intra-operative hypotension and need for inotropes are common predictors of AKI 
after liver transplantation (O’Riordan A, et al. 2007). The greatest intra-operative 
haemodynamic derangement typically occurs at the time of graft reperfusion, and post 
reperfusion syndrome, the extreme manifestation, is associated with a marked increase 
in the frequency of severe renal impairment (Paugam-Burtz C, et al. 2009). Similarly, 
blood transfusion requirements have been associated with AKI in many observational 
studies (Chen J, et al. 2011), probably reflecting the severity of surgical haemorrhage. 
Alternatively, excessive transfusion may play a causal role and increase blood losses.  
The administration of a calcineurin inhibitor further compromises renal perfusion 
and function. Tacrolimus and cyclosporine cause an acute, dose-dependent, renal 
vasoconstriction and fall in glomerular filtration rate. Such effects have been attributed 
to an imbalance between vasoconstricting and vasodilating substances including 
endothelin and prostaglandins that are also implicated in the pathogenesis of 
hepatorenal syndrome (Arroyo V, et al. 1996). It has therefore been postulated that the 
greater haemodynamic and neuro-humoral derangement of cirrhotic patients may 
result in an increased susceptibility to the nephrotoxic effects. Delayed and lower dose 
peri-operative tacrolimus has been demonstrated to be beneficial for short term post-
transplant renal function. 
Despite the identification of multiple risk factors for AKI after liver transplantation 
it is clear when comparing the incidence of AKI in different populations and time 
periods that other factors are contributing. For example, in an American study of 
patients transplanted in the early 1990s with a mean baseline estimated glomerular 
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filtration rate of 78 ml/min/1.73m2, who received predominantly cyclosporine, the 
incidence of AKI stage 1-3 AKI was 36% (Iglesias JI, et al. 2010). In an Irish study of 
patients transplanted 1993 to 2004 with a pre-operative prevalence of stage 3-5 chronic 
kidney disease of 35%, mean MELD score of 31, and mean 2 week tacrolimus and 
cyclosporine trough levels of  8.7 ng/mL and 150 ng/mL respectively, 37% of patients 
developed at least RIFLE class Injury (O’Riordan A, eta al. 2007). Moreover, in a 
contemporary cohort of our transplant population, even with comparatively low 
MELD scores, better pre-transplant renal function and renal sparing 
immunosuppression being administered to a quarter of patients, the incidence of AKI 
was similar (Leithead JA, et al. 2012). Detailed donor data is lacking in many such 
studies. However, given that graft quality has evolved in recent years in parallel with 
the discrepancy between supply and demand for liver transplantation, and that donor 
characteristics differ significantly between countries, this suggests that the liver graft 
itself may be playing a role in the aetio-pathogenesis of AKI. 
The systemic cytokine release responsible of the SIRS seems to be the common 
pathway for the multiple organ dysfunction of sepsis and other inflammatory disorders 
(Bone R. 1996). Acute kidney injury occurring in the context of inflammatory disease 
states such as sepsis, pancreatitis and trauma has largely recognised its aetiology in the 
occurrence of a systemic inflammatory response that mediates renal damage. 
The leading paradigm that AKI occurring in sepsis is due to renal ischemia 
associated with a decline in global renal blood flow as it was reported in hypodynamic 
shock has recently been reviewed (Laffey JC, et al. 2002). Immunologic factors have 
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been accounted in mediating renal injury during sepsis, with TNF-, IL-1 and IL-6 
involved as major players (Cunningam PN, et al. 2002; Jo SK, et al. 2002).  
In the setting of severe acute pancreatitis, cytokines are reported as main 
inflammatory mediators participating in renal failure. Different studies proved an 
increase of inflammatory cytokines linked to the severity of acute pancreatitis and 
TNF- has been primary involved in inducing renal injury through different 
mechanisms (Hirota M, et al. 2000). 
An intense and long-lasting inflammatory response has been reported in major burn 
trauma patients, with a persistent and marked increased levels of TNF, IL-8, IL-6 and 
monocyte chemoattractant protein-1. The activation of an inflammatory response is 
reported to precede the acute increase in plasma creatinine concentration in patients 
with major burns, suggesting for this a role in the development of kidney failure 
(Steinvall I, et al. 2008). 
A strong association between SIRS and acute renal dysfunction was also reported 
in patients with non-paracetamol-induced acute liver failure (Leithead JA, et al. 2009) 
Evidence supporting the association between IRI and the development of AKI are 
strongly supported by the recent literature reporting increased incidence of renal 
dysfunction following graft preservation injury (Leithead JA, et al. 2012; Cabezuelo 
JB, et al. 2006; Glanemann M, et al. 2004; Bilbao I, et al. 1997). 
Graft dysfunction was a recognised risk factor for development of acute renal 
failure during the first week post-OLT in multivariate analysis (Cabezuelo JB, et al. 
2006). The incidence of haemodialysis was reported to be significantly higher in 
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patients with severe preservation injury, with an increased risk of more than 6 folds 
for haemodialysis in these patients compared to patients with minor hepatic injury 
(Glanemann M, et al. 2004). A positive correlation between post-transplant 
preservation injury and renal insufficiency and need for postoperative dialysis was 
also reported (Bilbao I, et al. 1997).  
Hepatic ischemia reperfusion injury plays a critical role in the pathogenesis of 
AKI after liver transplantation from DCDs also. The greater injury of these organs 
following the prolonged warm ischemic time was accompanied by a 1.7-fold 
increased incidence of AKI (Leithead JA, et al. 2012). 
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METHODS 
 
This is a retrospective single-centre study of adult patients (age>16 years) who 
underwent liver transplantation at University Hospital Birmingham (UHB) National 
Health Service (NHS) Foundation Trust from January 2007 to December 2014. The 
project was approved by University Hospitals Birmingham NHS Foundation Trust's 
Clinical Audit Registration and Management System (CARMS-11695) and by the 
Human Biomaterials Resource Centre, College Medical & Dental 
Sciences, University of Birmingham (Application Number: 14-196). 
 
Clinical data considered 
Characteristics of recipient at transplant (age; gender; race; BMI; aetiology of end 
stage liver disease; presence of hepatocarcinoma – HCC; hepatitis C virus – HCV, 
hepatitis B virus – HBV and cytomegalovirus – CMV infections; comorbidities such 
as diabetes mellitus and hypertension; time on the waiting list); recipient renal and 
liver function in the immediate pre-transplant period (serum creatinine, glomerular 
filtration rate – GFR, serum sodium, renal replacement therapy; MELD score, 
International Normalized Ratio – INR, serum bilirubin and albumin); renal function in 
the post-transplant period (daily serum creatinine and need for renal replacement 
therapy within one week post-operatively); donor and graft variables (type of donation 
– DBD vs. DCD; cause of death; donor age, gender, race, BMI, CMV infection; 
functional donor warm ischaemia time, graft cold ischaemia time, rewarming 
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ischaemia time, donor risk index); intra-operative parameters (red blood cell, plasma 
and platelet transfusions; use of inotropes; duration of transplant); indicators of initial 
graft function (alanine aminotransferase – ALT, aspartate aminotransferase – AST, 
INR and bilirubin within one week after surgery) were considered.  
Baseline recipient characteristics were extracted from the hospital administrative 
databases at the time of admission; baseline bloods were extracted based on the last 
measurement before transplantation. 
Functional donor warm ischaemia time (dWIT) is exclusively related to DCD 
donors and was defined as the time from the decline of patient’s systolic arterial 
pressure below 50 mmHg and/or arterial oxygen saturation below 70% to cold 
perfusion. It includes the mandatory 5-minute period of waiting, after asystole, before 
donor incision. 
Graft cold ischaemia time (CIT) was defined as the time from the cold perfusion to 
the liver out of ice before the implantation in the recipient. 
Rewarming ischaemia time corresponds to the recipient warm ischaemia time 
(rWIT) and was defined as the time from liver out of ice to hepatic artery reperfusion 
into the recipient. 
Donor risk index (DRI) was calculated as: exp[(0.154 if 40≤ age <50) + (0.274 if 
50≤ age <60) + (0.424 if 60≤ age <70) + (0.501 if 70 ≤ age) + (0.079 if cause of death 
= anoxia) + (0.145 if cause of death = cardiovascular accident) + (0.184 if cause of 
death = other) + (0.176 if race = African American) + (0.126 if race = other) + (0.411 
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if DCD)+(0.422 if partial/split)+(0.066 ((170–height)/10))+(0.105 if regional 
share)+(0.244 if national share)+(0.010×cold time)]. (Feng S, et al. 2006) 
Primary end points were the occurrence of biliary complications (cholangitis, leak, 
anastomotic strictures, and IC in particular) and development of AKI. Secondary end 
point was the evaluation of ischemia-reperfusion injury damage on the basis of 
transaminases, bilirubin and INR over the first week post-transplant and the 
appearance of bile duct on histological examination. 
IC was defined as non-anastomotic biliary stricture in the presence of a patent 
hepatic artery confirmed on magnetic resonance cholangiopancreatography (MRCP) 
or endoscopic retrograde cholangiopancreatography by one or two consultant 
specialist radiologists. 
Acute kidney injury was defined according to the recent KDIGO Guideline (Kidney 
Disease: Improving Global Outcomes Acute Kidney Injury Work Group 2012) as an 
increase in serum creatinine (sCr) by ≥ 0.3 mg/dl within 48 hours or an increase in sCr 
to ≥ 1.5 times baseline within the first 7 days after transplantation and classified as: 
Stage 1, increase ≥ 0.3 mg/dl or increase of 1.5-1.9 fold from baseline; Stage 2, 
increase of 2-2.9 fold from baseline; Stage 3, increase > 3-fold from baseline or 
increase in sCr to ≥ 4.0 mg/dl or initiation of renal replacement therapy. 
Glomerular filtration rate was estimated by the Modification of Diet in Renal 
Disease (MDRD) Study equation: [186 × sCr (mg/dL)−1.154 × age (years)−0.203 × 
1.212 (if black) × 0.742 (if female)] (Gonwa TA, et al. 2004). 
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Evaluation of bile duct histology 
A series of consecutive patients with sample of bile duct available, were selected. 
The bile duct sample was retrieved after portal and arterial reperfusion of the liver, 
before the procedure of biliary anastomosis. 
Bile duct samples were immediately preserved in 10% paraformaldehyde, then 
embedded in paraffin, sectioned (3-4 m thick) and stained with hematoxylin-eosin 
(H&E) for histological evaluation. 
Severity of donor bile duct injury was assessed and scored on the basis of the 
following criteria, modified by Hansen et al (Hansen T, et al. 2012) and op den Dries 
et al (op den Dries S, et al. 2014):  
- Biliary epithelial cell loss (absence of the epithelial lining, leading to denuded 
subepithelial stroma) – no epithelial cell loss, <50% of bile duct with absent 
epithelial lining; >50% of bile duct with absent epithelial lining. 
- Mural stroma necrosis (loss of nucleated cells in duct wall) – <25% of bile duct 
circumference; 25-50% of bile duct circumference; >50% of bile duct 
circumference. 
- Intramural bleeding (erythrocyte extravasation into the bile duct wall) – ≤50% 
of the bile duct wall; >50 % of the bile duct wall. 
- Inflammation (occurrence of leukocytes anywhere in the bile duct wall) – no 
inflammation, at least one high-power field (HPF) with >10 leukocytes; at least 
one HPF with >50 leukocytes. 
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- Peribiliary vascular plexus (loss of endothelial cells or subendothelial oedema) 
– no injury; ≤50 % vessels damaged; >50 % vessels damaged. 
- Arteriolonecrosis (complete loss of vital cells in the wall of arteriole/small 
artery) – no injury; ≤50 % vessels damaged; >50 % vessels damaged. 
- Thrombosis – absent; present. 
- Periluminal PBGs (detachment of the cells from the basement membrane and/or 
disappearance of epithelial cells from the glands) – no signs of injury; ≤50% 
detachment/loss of cells; >50% detachment/loss of cells. 
- Deeper PBGs, located at the junction of bile duct wall stroma and muscular 
layer (detachment of the cells from the basement membrane and/or 
disappearance of epithelial cells from the glands) – no signs of injury; ≤50% 
detachment/loss of cells; >50% detachment/loss of cells. 
 
Evaluation of cholangiocyte apoptosis 
Cholangiocyte apoptosis in periluminal and PBGs was evaluated by quantitative 
terminal deoxy-nucleotidyl transferase dUTP-mediated nick-end labeling (TUNEL) 
analysis (Apoptag; Chemicon, Billerica, MA) on bile duct sections. Sections were 
analyzed in a coded manner using BX-51 light microscopy (Olympus, Tokyo, Japan) 
with a video cam (Spot Insight; Diagnostic Instrument, Sterling Heights, MI) and 
processed with an Image Analysis System (Delta Sistemi, Rome, Italy).  
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Evaluation of cholangiocyte proliferation 
Cholangiocyte proliferation was studied in bile duct sections by proliferating cell 
nuclear antigen (PCNA) immunohistochemical expression. Sections were 
deparaffinized and endogenous peroxidase activity was blocked by a 30-min 
incubation in methanolic hydrogen peroxide (2.5%). Later, the endogenous biotin was 
blocked by a biotin blocking system (code X0590; Dako, Copenhagen, Denmark) 
according to the instructions supplied by the vendor. Sections were then hydrated in 
graded alcohol and rinsed in 1 PBS (pH 7.4) before applying the selected primary 
antibody. Sections were incubated overnight at 4°C with PCNA polyclonal antibodies 
(Santa Cruz Biotechnology, Milan, Italy). The following day, samples were rinsed 
with PBS for 5 min, incubated for 20 min at room temperature with secondary 
biotinylated antibody (LSAB Plus system; Dako, Milan, Italy) and then with Dako 
ABC (LSAB Plus system; Dako), and finally developed with 3,3=-diaminobenzidine. 
To confirm the specificity of immunoreaction, negative controls were performed for 
all immunoreactions. We measured the percentage of PCNA-positive small and large 
cholangiocytes (36).  
All the available periluminal and deep PBGs were evaluated for both apoptosis and 
proliferation. An easy cell counting method was applied, as previously reported by 
Bologna-Molina et al (Bologna-Molina R, et al. 2011). Briefly, a 6x 6 fixed grid is 
placed over the picture of the slide taken at fixed magnification, i.e. x40, and the cell 
counting is started in the top left frame and finished in the top right frame following a 
fixed path. Numbers of both negative and positive cells were counted manually in each 
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image and scheduled separately. The resulting data were calculated as follows: % 
positive cells = positive nuclei cells ⁄ total cells nuclei x 100. 
 
Statistical analyses  
Continuous variables were tested for normality, non-normal variables have been 
summarised using medians and inter-quartile range with the Mann-Whitney test used 
for comparisons, and normal variables are described using mean and standard 
deviation and comparisons tests using t-tests. Chi-squared or Fishers' exact tests were 
used to make comparisons for categorical variables. 
Data were analyzed using the SPSS 24 package. p <0.05 was considered statistically 
significant unless otherwise stated.  
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RESULTS 
 
Recipient, donor and graft characteristics from pre- to post-transplant 
From the entire cohort of 1150 patients, 1060 liver transplant recipients (813 from 
DBD and 247 from DCD) were considered. Ninety patients were excluded from the 
analysis because of acute hepatic failure (n. 66), living donor (n. 7), combined liver-
kidney (n. 16) transplantation, previous history of kidney transplant (n. 1). The 
distribution of liver transplants performed at UHB over time is reported in Table 1 and 
in Figure 2.  
The baseline characteristics of DBD vs. DCD recipients are reported in Table 2. 
DCD recipients, compared to DBD, had significantly better hepatic and renal functions 
before LT, as showed by significantly low median MELD score (12.6 vs. 15.5; 
p<0.001), serum bilirubin level (34 vs. 53; p<0.001), INR (1.3 vs. 1.4; p<0.001) and 
sCr (75 vs. 79; p=0.033) levels.  
Furthermore, DCD had a higher DRI than DBD (2.70 vs. 1.87; p<0.001) but, after 
exclusion of DCD status from the formula, there was a reversal of the trend towards a 
significant higher DRI in the DBD group (1.87 vs. 1.79; p=0.015) (Table 3).  
In addition, DBD liver recipients had a significantly longer CIT (8.4 vs. 7.1; 
p<0.001) and rWIT (39 vs. 37; p=0.0157) compared to DCD (Table 3).  
Recipients from DCD had higher postoperative peak ALT and AST compared to 
DBD (Table 4). 
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The occurrence of biliary complications was higher in DCD liver transplant 
recipients (85/247; 34%) compared to DBD (166/813; 20%) (p<0.001), in particular 
incidence of IC was significantly higher in DCD (Table 5). 
The incidence of AKI was 59.3% (629/1060 recipients) and was significantly 
higher in DCD (160/247, 64.8%) compared to DBD (469/813, 57.7%) recipients 
(p=0.047). The classification of AKI according to KDIGO Guideline is reported in 
Table 6. There were no significant differences in the incidence of AKI stages 1 and 2, 
whereas DCD showed a significantly higher incidence of AKI stage 3 compared to 
DBD (p<0.001). 
 
Evaluation of bile duct histology 
Sixty-two patients had the bile duct sample available for histological evaluation. 
These were comparable in terms of age (p=0.085), pre-transplant liver and renal 
function (INR p=0.327; bilirubin p=0.147; creatinine p=0.802; MELD score 
p=0.702), liver graft warm (p=0.150) and cold ischaemia time (p=0.166) with the 
entire cohort population. 
Severity of donor bile duct injury was assessed and scored as reported in Table 7. 
A significantly higher number of DCD patients presented necrosis >50% of the bile 
duct wall [DCD 14/28 (50%), DBD 9/34 (26.5%) p=0.056], PVP damage [DCD 8/28 
(29%), DBD 3/34 (9%); p=0.053] and periluminal PBGs damage [DCD 20/28 (71%), 
DBD 14/34 (41%); p=0.016].  
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No differences have been detected in terms of biliary epithelial cell loss, intramural 
bleeding, inflammation, arteriolonecrosis, thrombosis and deep PBGs damage. 
Severe histological injury was defined when mural stroma necrosis >50%, 
periluminal PBGs injury >50% and PVP damage >50% occurred (Figure 3). Sever 
histological injury was significantly more frequent in DCD liver transplant patients 
[15/28 (53.6%)] compared to DBD [7/34 (20.6%)] (p=0.007). 
 
Evaluation of cholangiocytes apoptosis and proliferation 
Livers transplanted from DCD demonstrate increased apoptosis and reduced 
proliferation at the level of both periluminal and deep PBGs, even if this not reach 
statistical significance (Table 8A; Figures 4, 5). 
Otherwise, a significant increased apoptosis and decreased proliferation was 
evidenced in both periluminal (Tunel assay p=0.029; PCNA expression p=0.029) and 
deep PBGs (Tunel assay p=0.002; PCNA expression p=0.006) from bile duct sample 
with severe histological injury (Table 8B). This trend is maintained within DCD and 
DBD separately, but the small number of patients in the two groups reduced the 
statistical power of the results (Figures 6-9). 
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DISCUSSION 
 
Over the past 40 years, orthotopic liver transplantation has evolved from an 
experimental procedure to become the treatment of choice for patients with end-stage 
liver failure. In the past decades, advances in immunosuppressive therapy, organ 
preservation, surgical and anesthetic techniques and better management of post-
transplantation complications have led to further improvement in survival of patients 
receiving organ transplantation. 
The increasing request of organs has led to the more extensive use of the so-called 
marginal donors, in particular donors after circulatory death. 
Within this model of donation, a more severe degree of ischaemia-reperfusion 
injury is occurring, as evidenced by greater graft dysfunction and increasing peak 
perioperative transaminases, likely related to the added donor warm ischaemia time.  
The IRI seems to play a role on the pathogenesis of local and remote organ 
complications, leading in particular to biliary complications and development of 
systemic inflammatory response associated with the occurrence of acute kidney injury. 
Ischaemic injury in organs from DCD accumulated during the cold storage phase is 
exacerbated and multiplied by the initial phase of warm ischaemia, leading to an 
increased exposure to IRI and higher incidence of delayed graft function. Multiple 
pathways are implicated in IRI including cellular cascade systems, oxygen free 
radicals, and activation of T-cell lymphocytes.  
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Hepatic IRI acts locally, inducing hepatic tissue repair characterized by 
proliferation of hepatocytes, removal of necrotic tissue and restoration of the 
hepatocellular and hepatic microvascular architecture. Cholangiocytes lining the 
biliary ducts are very sensitive to ischaemic injury, in particular increased vulnerability 
of cholangiocytes during the reperfusion and prominent damage of bile ducts occurring 
after cold storage have been described (Noack K, et al. 1993; Brunner SM, et al. 2013). 
Recently, increased apoptosis and reduced proliferation of large bile duct and altered 
expression of biliary angiogenic factors have also been demonstrated (Mancinelli R, 
et al. 2015).  
A higher incidence of ischaemic-cholangiopathy has been reported in transplants 
from DCD donors compared to donation after DBD, probably due to the longer and 
complex ischemic damage in this model of donation. An important role has been 
hypothesized for the inadequate perfusion of PVP during the retrieval process, because 
the small arterial plexus surrounding the biliary tree could be poorly washed by some 
high viscosity solutions leading to micro-thrombotic complications during the 
reperfusion phase that exacerbate the ischemic damage to the biliary cells (Polack WG 
and Porte RJ, 2006). Moreover, the injury occurring at the PBGs seems to play a role 
in the development of biliary complications post-liver transplantation (op den Dries S, 
et al.2014).  
Donor warm ischemia duration also correlates with the postoperative systemic 
inflammatory response that could be responsible of remote organ damage, in particular 
acute kidney injury. 
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The systemic release of pro-inflammatory cytokines such as TNF-, IL-1, IL-6 
and IL-8, subsequent to reperfusion of the liver and responsible of the development of 
SIRS, seems to be the common pathway for the occurrence of renal damage that leads 
to acute kidney injury.  
Evidence supporting the association between IRI and the development of AKI are 
strongly supported by the recent literature reporting increased incidence of renal 
dysfunction following graft preservation injury. In particular the association between 
post-transplant graft dysfunction and AKI was reported (Cabezuelo JB, et al. 2006) as 
well as the increased risk of haemodialysis in patients with severe preservation injury 
(Glanemann M, et al. 2004). The greater injury of liver transplantation from DCD 
following the prolonged warm ischemic time, was accompanied by a 1.7-fold 
increased incidence of AKI (Leithead JA, et al. 2012). 
In our study we evaluated the role of two different models of ischaemia, DCD and 
DBD, in liver transplanted grafts, on the pathogenesis of local and remote organ 
complications.  
We retrieved clinical and laboratory data from a single high-volume transplant 
centre in UK, where DCD transplantations account for a quarter of the total transplant 
volume. 
The retrieval of bile duct samples before the duct to duct anastomosis in the 
recipient for histological assessment has also recently become a standard of care. 
Therefore, it has been possible to reassess the histological features and complete the 
immunohistochemistry study for apoptosis and proliferation at the bile duct level. 
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The incidence of bile duct complications, in particular the development of IC, was 
increased in DCD liver transplantation, as previously reported. The occurrence of AKI 
was also increased in transplants from DCD compared to DBD.  
Interesting results came from the histological evaluation of bile duct samples. 
Biliary epithelial cells loss is almost complete in the majority of bile ducts, 
suggesting the high degree of IRI suffered from these. Intramural bleeding >50% was 
also a common feature present in more than 50% of patients, irrespective of type of 
donation. 
Bile duct samples retrieved from DCD grafts expressed more severe injury at the 
histological level, as evidenced by the increased incidence of mural stroma necrosis, 
PVP damage and periluminal PBGs damage, defining the new feature of severe 
histological injury.  
The evaluation of apoptosis and proliferation of PBGs cholangiocythes showed 
increased damage as well as reduced reactivity in line with the damage: bile ducts with 
severe histological injury showed increased apoptosis and reduced proliferation as 
evaluated by Tunel assay and PCNA expression, both on periluminal and deep PBGs. 
The same trend was confirmed analysing apoptosis and proliferation in DCD and DBD 
separately, but the statistical significance was not reached probably in relation to the 
small number of samples for each model. 
Two patients only within the 62 group of patients with bile duct histology developed 
IC, therefore no statistical analysis was conducted. Otherwise both patients presented 
the severe histological injury of the bile duct. 
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The model of increased IRI in DCD livers seems to confirm the relation with local 
and remote organ damage as evidenced by the more severe damage of bile duct 
samples and the increased incidence of AKI. 
The higher incidence of IC development in DCD strongly suggests a relation 
between the occurrence of severe histological injury and alteration in bile duct repair 
mechanisms. 
This study shows an early picture of microscopic damage at the level of the bile 
duct soon after reperfusion of liver graft during transplantation, raising hypothesis to 
further evaluate those mechanisms leading to the development of bile duct non-
anastomotic strictures. 
A series of factors are reported to stimulate cholangiocytes proliferation in different 
cholangiopaties such as primary sclerosing cholangitis, primary biliary cirrhosis, 
polycystic liver disease and cholangiocarcinoma. During these pathologies, 
cholangiocytes, which in normal condition are in a quiescent state, begin to proliferate 
acquiring phenotypes of neuroendocrine cells, and start secreting different cytokines, 
growth factors, neuropeptides, and hormones to modulate cholangiocytes proliferation 
and interaction with the surrounding environment, trying to reestablish the balance 
between proliferation/loss of cholangiocytes for the maintenance of biliary 
homeostasis (Franchitto A, et al. 2012). Further studies are needed to define the role 
of long-term cholangiocyte reaction to the ischemia-reperfusion injury after liver 
transplantation in the development of biliary complications.  
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A continue cross-talk is also established between biliary cholangiocytes and 
endothelial cells of the PVP (Gaudio E, et al. 1996), with an interaction that mediates 
the adaptive changes of these cells during liver injury. 
Altered expression of biliary angiogenic factors (Vascular endothelia growth 
factors and Angiopoietins) has been demonstrated in animal models of IRI induced 
damage of intrahepatic cholangiocytes (Mancinelli R, et al. 2015), therefore future 
research will focus on the evaluation and measurement of angiogenic factors and 
related receptors after liver reperfusion, to better address the actual knowledge of bile 
duct reaction in liver transplantation. 
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TABLES 
Table 1. Liver transplants performed at Queen Elizabeth University Hospital 
Birmingham from 2007 to 2014. 
 
Year DBD [n. 813] DCD [n. 247] Total [n. 1060] 
2007 102 (12.5) 9 (3.6) 111 
2008 93 (11.4) 13 (5.3) 106 
2009 84 (10.3) 26 (10.5) 110 
2010 96 (11.8) 29 (11.7) 125 
2011 96 (11.8) 36 (14.6) 132 
2012 102 (12.5) 48 (19.4) 150 
2013 110 (13.5) 37 (15.0) 147 
2014 130 (16.0) 49 (19.8) 179 
 
Values are expressed as number (percentage). 
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Table 2. Baseline characteristics of DBD vs. DCD liver transplant recipients. 
   DBD [n. 813] DCD [n. 247] p-value 
Age – years 52 (42, 60) 57 (50, 62) <0.001 
Gender  Male 485 (59.7) 164 (66.4) 0.057  
Female 328 (40.3) 83 (33.6) 
Race  White  693 (85.2) 206 (83.4) 0.523  
Black  21 (2.6) 3 (1.2)  
Asian  70 (8.6) 27 (10.9)  
Other  27 (3.3) 10 (4.0)  
Unknown  2 (0.2) 1 (0.4) 
Height – m  1.7 (0.1) 1.7 (0.1) 0.612 
Weight – kg 78.5 (18.2) 78.4 (17.2) 0.543 
BMI – kg/m2 26 (23, 30) 26 (23, 29) 0.966 
HCC  150 (18.5) 85 (34.4) <0.001 
CMV  473 (58.2) 149 (60.3) 0.549 
HBV  40 (4.9) 13 (5.3) 0.009 
HCV  85 (10.5) 41 (16.6) 0.828 
Diabetes  179 (22.0) 71 (28.7) 0.029 
Hypertension  90 (11.1) 39 (15.8) 0.047 
MELD  15.5 (11.5, 20.7) 12.6 (9.4, 16.4) <0.001 
INR  1.4 (1.2, 1.8) 1.3 (1.1, 1.5) <0.001 
Bilirubin – umol/L 53 (26, 119) 34 (16.5, 63.5) <0.001 
Creatinine – umol/L 79 (63, 99) 75 (61, 95) 0.033 
Sodium – mEq/L 140 (137, 143) 141 (138, 143) 0.016 
Albumin – g/L 27 (22, 32) 27 (22, 32) 0.794 
GFR – ml/min/1.73m2 87 (65, 115) 92 (72, 112) 0079 
GFR <60 ml/min/1.73m2 155 (19.1) 27 (10.9) 0.003 
Dialysis   31 (3.8) 8 (3.2) 0.675 
 
Values are expressed as number (percentage) or median (interquartile range), as 
appropriate.  
BMI: body mass index; CMV: cytomegalovirus; DBD: donation after brain death; 
DCD: donation after circulatory death; HBV: hepatitis B virus; HCC: hepatocellular 
carcinoma; HCV: hepatitis C virus; GFR glomerular filtration rate; INR: 
international normalized ratio; MELD: model for end stage liver disease score. 
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Table 3. Donor, graft and intra-operative parameters of DBD vs DCD liver 
transplantation. 
 DBD [n. 813] DCD [n. 247] p-value 
Cause of  Trauma  2 (0.2) 2 (0.8) <0.001 
death Cerebrovascular 
accident  
52 (6.4) 36 (14.6)  
 Anoxia  495 (60.9) 125 (50.6)  
 Infection  23 (2.8) 6 (2.4)  
 Other  93 (11.4) 38 (15.4)  
 Unknown  148 (18.2) 40 (16.2)  
Age – years   49 (36, 60) 52 (39, 62) 0.041 
Gender  Male 386 (47.5) 142 (57.5) 0.023 
 Female 399 (49.1) 105 (42.5)  
Race  White  793 (97.5) 245 (99.2) 0.099 
 Black  3 (0.4) 0 (0.0)  
 Asian  13 (1.6) 1 (0.4)  
 Other  0 (0.0) 1 (0.4)  
 Unknown  4 (0.5) 0 (0.0)  
Height – m  1.7 (1.62, 
1.76) 
1.71 (1.62, 
1.79) 
0.208 
Weight – kg 75 (65, 85) 75 (65, 81) 0.183 
BMI – kg/m2 25.96 (22.92, 
29) 
24.97 (23.11, 
27.76) 
0.018 
CMV  392 (48.2) 121 (49.0) 0.883 
DRI  1.87 (1.59, 
2.18) 
2.70 (2.25, 
3.18) 
<0.001 
DRI – no DCD status 1.87 (1.59, 
2.18) 
1.79 (1.49, 
2.11) 
0.015 
CIT – hours  8.4 (7.0, 10.0) 7.1 (6.0, 8.2) <0.001 
rWIT – mins  39 (34, 44) 37 (32, 43) 0.0157 
dWIT – mins   18 (14,22)  
Blood transfusions – unit  2 (0, 4) 2 (0, 4) 0.367 
Plasma transfusions – unit 7 (4, 10) 6.5 (4, 12) 0.525 
Platelets transfusions – unit 10 (0, 15) 5 (0, 10) 0.170 
Use of inotropes  363 (44.6) 132 (53.4) 0.015 
Duration of transplant – hours 5.2 (4.4, 6.1) 5.1 (4.3, 5.8) 0.201 
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Values are expressed as number (percentage) or median (interquartile range), as 
appropriate. 
BMI: body mass index; CIT: cold ischaemia time; CMV: cytomegalovirus; DBD: 
donation after brain death; DCD: donation after circulatory death; DRI: donor risk 
index; dWIT: donor warm ischaemia time; rWIT: recipient warm ischaemia time.  
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Table 4. Indicators of early post-operative graft function. 
 
DBD [n. 813] DCD [n. 247] p-value 
AST peak – IU/L   668 (193, 1317) 784.5 (160, 1891.75) 0.056 
ALT peak – IU/L 598.5 (325.75, 991.5) 949 (544, 1741) <0.001 
Bilirubin peak – umol/L   85 (52, 141.5)  82 (50, 128)  0.428 
INR peak 1.6 (1.4, 1.9)  1.7 (1.48, 2)  0.078 
 
Values are expressed as number (percentage) or median (interquartile range), as 
appropriate. 
ALT: alanine aminotransferase; AST: aspartate aminotransferase; DBD: donation 
after brain death; DCD: donation after circulatory death; INR: international 
normalized ratio. 
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Table 5. Biliary complications in DBD vs. DCD liver transplant recipients. 
 DBD [n. 813] DCD [n. 247 p-value 
Cholangitis 39 (4.8) 11 (4.3) 0.823 
Bile leak 21 (2.6) 12 (4.8) 0.071 
Anastomotic strictures 104 (12.8) 36 (14.4) 0.469 
Ischemic cholangiopathy 2 (0.2) 26 (10.6) <0.001 
 
Values are expressed as number (percentage). 
DBD: donation after brain death; DCD: donation after circulatory death. 
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Table 6. Classification of AKI in DBD vs. DCD liver transplant recipients. 
 
AKI DBD [n. 813] DCD [n. 247] p-value 
Stage 1 167 (20.5) 48 (19.4) 0.704 
Stage 2 154 (18.9) 36 (14.6) 0.117 
Stage 3 148 (18.2) 76 (30.8) <0.001 
 
Values are expressed as number (percentage). 
AKI: acute kidney injury; DBD: donation after brain death; DCD: donation after 
circulatory death. 
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Table 7. Histological evaluation of bile duct injury 
 
Injury DBD [n. 34] DCD [n. 
28] 
p-value 
Biliary epithelial cell loss >50% 32 (94.1) 28 (100) 0.497 
Mural stroma necrosis >50% 9 (26.5) 14 (50.0) 0.056 
Intramural bleeding >50 % 22 (64.7) 16 (57.1) 0.543 
Inflammation at least one HPF with 
>10 leukocytes 
8 (23.5) 2 (7.2) 0.187 
PVP damage >50%  3 (8.8) 8 (28.6) 0.053 
Arteriolonecrosis >50% 4 (11.8) 6 (21.4) 0.326 
Thrombosis - 1 (3.6) 0.452 
Periluminal PBGs damage >50% 14 (41.2) 20 (71.4) 0.017 
Deep PBGs damage >50% 2 (5.9) 5 (17.9) 0.228 
 
Values are expressed as number (percentage). 
DBD: donation after brain death; DCD: donation after circulatory death; PBGs: 
peribiliary glands; PVP: peribiliary vascular plexus. 
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Table 8. Measurement of biliary apoptosis by Tunel assay and proliferation by PCNA 
expression in periluminal and deep peribiliary glands in DCD vs DBD liver transplant 
patients (A) and in patients with mild and sever histological injury (B) 
 
A DBD [n. 34] DCD [n. 28] 
 Periluminal Deep Periluminal Deep 
Biliary 
apoptosis 
46.3 (28.3, 
64.5) 
53.6 (26.0, 
62.3) 
47.0 (31.1, 
55.5) 
59.1 (31.5, 
61.8) 
Proliferation 23.6 (12.0, 
48.9) 
34.5 (14.5, 
61.9) 
12.0 (6.2, 
39.0) 
29.5 (9.6, 
50.9) 
 
 
B Mild histological injury Severe histological injury 
 Periluminal Deep Periluminal Deep 
Biliary 
apoptosis 
32.7 (27.5, 
57.7) 
51.2 (20.8, 
60.5) 
56.0 (48.1, 
64.0) 
61.9 (59.1, 
64.3) 
Proliferation  25.7 (11.5, 
46.3) 
45.2 (14.9, 
61.6) 
9.8 (3.2, 38.3) 14.6 (5.9, 
32.6) 
 
Values are expressed as median (interquartile range). 
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FIGURES 
 
Figure 1. Procedure and timing of organ retrieval in donation after circulatory death 
(DCD) and brain death (DBD). 
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Figure 2. Liver transplants performed at Queen Elizabeth University Hospital 
Birmingham from 2007 to 2014. 
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Figure 3. Severe histological injury. 
 
Signs of severe injury: mural stroma necrosis as evidenced by the complete loss of 
nucleated cells in duct wall; loss of endothelial cells from the peribiliary vascular 
plexus; detachment of the cells from the basement membrane and disappearance of 
epithelial cells from the periluminal peribiliary glands. Associated loss of the biliary 
epithelial cell loss and intramural bleeding. (Original magnification x20) 
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Figure 4. Apoptosis of peribiliary glands (Tunel assay). 
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Figure 5. Proliferation of peribiliary glands (PCNA expression). 
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Figure 6. Biliary apoptosis by TUNEL assay in periluminal peribiliary glands with 
severe histological injury in DBD (p=0.130) and DCD (p=0.001) liver transplant 
patients. 
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Figure 7. Biliary apoptosis by TUNEL assay in deep PBG with severe histological 
injury in DBD (p=0.027) and DCD (p=0.098) liver transplant patients. 
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Figure 8. Biliary proliferation by PCNA expression in periluminal PBG with severe 
histological injury in DBD (p=0.031) and DCD (p=0.467) liver transplant patients. 
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Figure 9. Biliary proliferation by PCNA expression in deep PBG with severe 
histological injury in DBD (p=0.054) and DCD (p=0.108) liver transplant patients. 
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